Page 322 - Read Online

Rutledge et al. Hepatoma Res 2019;5:31 I http://dx.doi.org/10.20517/2394-5079.2019.19 Page 11 of 12

2014;61:530-7.
12. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.
13. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic
patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
14. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
15. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, et al. High incidence of hepatocellular carcinoma following
successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65:1070-1.
16. Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al. Outcomes after successful direct-acting antiviral therapy for
patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.
17. Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C
in the era of DAAs: Too alarming? J Hepatol 2016;65:1068-9.
18. Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, et al. Is the risk of neoplastic recurrence increased after
prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol 2017;66:236-7.
19. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol
2016;65:663-5.
20. Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, et al. The short-term incidence of hepatocellular carcinoma is not increased after
hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology 2018;67:2244-53.
21. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, et al. Sustained virologic response by direct antiviral agents reduces the
incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017;89:476-83.
22. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.
23. Carrat F. Clinical outcomes in HCV-infected patients treated with direct acting antivirals-18 month post-treatment follow-up in the
french anrs CO22 hepather cohort study. J Hepatol 2016;64:S215.
24. El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, et al. Increased recurrence rates of hepatocellular carcinoma after
DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis. J Viral Hepat 2018;25:623-30.
25. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
26. Pol S. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma. J Hepatol 2016;65:734-
40.
27. Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically
plausible or an epiphenomenon? World J Hepatol 2018;10:267-76.
28. Grandhe S, Frenette CT. Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy
for Patients With Chronic Hepatitis C Virus Infection. Gastro Hepat 2017;13:421.
29. Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, et al. Incidence and pattern of” de novo” hepatocellular carcinoma in HCV
patients treated with oral DAAs. In. Hepatology: Wiley-blackwell 111 river st, hoboken 07030-5774, NJ USA; 2016.
30. Renzulli M, Buonfiglioli F, Conti F, Brocchi S, Serio I, et al. Imaging features of microvascular invasion in hepatocellular carcinoma
developed after direct-acting antiviral therapy in HCV-related cirrhosis. Eur Radiol 2018;28:506-13.
31. Demirjian A, Peng P, Geschwind JFH, Cosgrove D, Schutz J, et al. Infiltrating hepatocellular carcinoma: seeing the tree through the
forest. J Gastrointest Surg 2011;15:2089-97.
32. Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, et al. Drop-out rate from the liver transplant waiting list due to HCC
progression in HCV-infected patients treated with direct acting antivirals. Liver Transpl 2017;23:1103-12.
33. Fangazio S, Camatta D, Minh MT, Ceriani E, Minisini R, et al. Treatment failure after interferon-free treatment of hepatitis C as a
clue of a yet undetected hepatocellular carcinoma. J Hepatol 2018;68:212-3.
34. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran
patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
35. Hengst J, Schlaphoff V, Deterding K, Falk C, Manns M, et al. DAA-induced HCV clearance does not restore the altered cytokine and
chemokine milieu in patients with chronic hepatitis C. J Hepatol 2016;64:S417-S8.
36. Tachi Y, Hirai T, Kojima Y, Ishizu Y, Honda T, et al. Liver stiffness measurement predicts hepatocellular carcinoma development in
patients treated with direct-acting antivirals. JGH Open 2017;1:44-9.
37. Adhoute X, Castellani P, Bourlière M. Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma. Transl
Gastroenterol Hepatol 2017;2:110.
38. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, et al. Delisting of liver transplant candidates with chronic
hepatitis C after viral eradication: A European study. J Hepatol 2016;65:524-31.
39. Munoz SJ, Reich DJ, Rothstein KD, Xiao GS, Patel V, et al. Curing decompensated wait listed HCV patients with the new DAAs: the
potential significant impact on liver transplant wait list and organ allocation. Hepatology 2015;62:311A.
40. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype
1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis
2016;16:685-97.